NRX Other Current Liab from 2010 to 2025

NRXP Stock  USD 2.07  0.01  0.48%   
NRX Pharmaceuticals Other Current Liabilities yearly trend continues to be relatively stable with very little volatility. Other Current Liabilities is likely to drop to about 10.7 M. During the period from 2010 to 2025, NRX Pharmaceuticals Other Current Liabilities destribution of quarterly values had range of 42.7 M from its regression line and mean deviation of  6,931,431. View All Fundamentals
 
Other Current Liabilities  
First Reported
2017-09-30
Previous Quarter
11.7 M
Current Value
16.2 M
Quarterly Volatility
7.5 M
 
Covid
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 41.8 K, Interest Expense of 218.5 K or Selling General Administrative of 19.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Latest NRX Pharmaceuticals' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of NRX Pharmaceuticals over the last few years. It is NRX Pharmaceuticals' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

NRX Other Current Liab Regression Statistics

Arithmetic Mean5,526,395
Geometric Mean121,146
Coefficient Of Variation199.97
Mean Deviation6,931,431
Median7,589
Standard Deviation11,051,061
Sample Variance122.1T
Range42.7M
R-Value0.47
Mean Square Error101.5T
R-Squared0.22
Significance0.06
Slope1,099,409
Total Sum of Squares1831.9T

NRX Other Current Liab History

202510.7 M
202416.2 M
20235.3 M
20225.8 M
20217.7 M
202042.7 M
2019 7589.0

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Other Current Liab, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Liabilities16.2 M10.7 M

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.